Search research articles
Contact Us
Filters
Showing results (561-570 of 573) with videos related to
Page
of 58
Sort By:
Blood
|
December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
Jeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
Nature Biotechnology
|
November 2, 2024
Development of compact transcriptional effectors using high-throughput measurements in diverse contexts
Josh Tycko, Mike V Van, Aradhana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2021
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Jennifer A Foltz, Brian T Hess, Veronika Bachanova, et al.
American Journal of Hematology
|
January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study
Brian T Hess, Anshu Giri, Yeonhee Park, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 29, 2020
Metabolic precision labeling enables selective probing of O-linked <i>N</i>-acetylgalactosamine glycosylation
Marjoke F Debets, Omur Y Tastan, Simon P Wisnovsky, et al.
Nature Genetics
|
April 11, 2017
Population- and individual-specific regulatory variation in Sardinia
Mauro Pala, Zachary Zappala, Mara Marongiu, et al.
BMC Psychiatry
|
June 3, 2014
Study protocol: The Whitehall II imaging sub-study
Nicola Filippini, Enikő Zsoldos, Rita Haapakoski, et al.
Blood Advances
|
November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium
John Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Blood Advances
|
August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study
Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.
Page
of 58
Search research articles
Search
Showing results (561-570 of 573) with videos related to
Sort By:
Page
of 58
Blood
|
December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma
Jeremy S Abramson, David J Straus, Nancy L Bartlett, et al.
Nature Biotechnology
|
November 2, 2024
Development of compact transcriptional effectors using high-throughput measurements in diverse contexts
Josh Tycko, Mike V Van, Aradhana, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2025
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Sarah C Rutherford, Hongli Li, Alex F Herrera, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 9, 2021
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Jennifer A Foltz, Brian T Hess, Veronika Bachanova, et al.
American Journal of Hematology
|
January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study
Brian T Hess, Anshu Giri, Yeonhee Park, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 29, 2020
Metabolic precision labeling enables selective probing of O-linked <i>N</i>-acetylgalactosamine glycosylation
Marjoke F Debets, Omur Y Tastan, Simon P Wisnovsky, et al.
Nature Genetics
|
April 11, 2017
Population- and individual-specific regulatory variation in Sardinia
Mauro Pala, Zachary Zappala, Mara Marongiu, et al.
BMC Psychiatry
|
June 3, 2014
Study protocol: The Whitehall II imaging sub-study
Nicola Filippini, Enikő Zsoldos, Rita Haapakoski, et al.
Blood Advances
|
November 7, 2025
Outcomes for CART as 2L vs 3L vs 4L or Beyond in Aggressive B-cell Lymphoma: Real World Evidence from the ABC Consortium
John Seng Wang, Brandon Lee Ellsworth, Megan Melody, et al.
Blood Advances
|
August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study
Alex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.
Page
of 58